A new €32 million project aimed at understanding drug-induced liver injury is the latest of several collaborative efforts that could help drug firms better test for candidate-killing toxicity ...

This article reviews the promises and challenges in developing and validating biomarkers that could help HCPs distinguish DILI from other causes of liver injury and identify the causative drug.

Abstract and Introduction Current Status of DILI Biomarkers Promising Avenues for Discovery of New DILI Biomarkers Next Steps References The lymphocyte transformation test is commercially ...

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001). Article PubMed Google Scholar ...

"GLDH will allow drug developers to properly determine the onset of liver injury in clinical trials for novel therapies to treat patients with muscle disease, where the traditional DILI biomarkers ...

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), drug-induced liver injury (DILI) is the leading cause of acute liver failure in the U.S. It is also a leading ...

CAMBRIDGE, England, June 10, 2025--CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal ...

New biomarkers could improve early detection and monitoring of kidney injury Date: January 6, 2025 Source: Boston Medical Center Summary: Researchers have identified six new biomarkers that could ...